Molecular Templates, Inc.

MTEM

...

MTEM: Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer.

Show MTEM Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of MTEM by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by MTEM's directors and management

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

Patent Title: Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes Aug. 09, 2022
Patent Title: Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation Jul. 19, 2022
Patent Title: De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same Jun. 21, 2022
Patent Title: Mhc class i epitope delivering polypeptides Apr. 26, 2022
Patent Title: Multivalent cd20-binding molecule comprising shiga toxin a subunit effector polypeptides and enriched compositions thereof Feb. 15, 2022
Patent Title: Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds Jan. 18, 2022
Patent Title: Cd20-binding proteins comprising shiga toxin a subunit effector regions for inducing cellular internalization and methods using same Oct. 12, 2021
Patent Title: Pd-l1 -binding molecules comprising shiga toxin a subunit scaffolds Oct. 05, 2021
Patent Title: Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof Aug. 31, 2021
Patent Title: Cell-targeting molecules comprising protease-cleavage resistant, shiga toxin a subunit effector polypeptides and carboxy-terminal moieties Oct. 27, 2020
Patent Title: Predictive biomarker for hypoxia-activated prodrug therapy Sep. 01, 2020
Patent Title: Aziridine containing dna alkylating agents Jun. 02, 2020
Patent Title: Th-302 solid forms and methods related thereto May. 19, 2020
Patent Title: Cd20-binding immunotoxins for inducing cellular internalization and methods using same Oct. 22, 2019
Patent Title: Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity Sep. 24, 2019
Patent Title: Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof Aug. 27, 2019
Patent Title: Th-302 solid forms and methods related thereto Nov. 20, 2018
Patent Title: Predictive biomarker for hypoxia-activated prodrug therapy Sep. 11, 2018
Patent Title: Cytotoxic heteromeric protein combinatorial libraries May. 11, 2010

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on MTEM's company Twitter account

WallStreetBets

Number of mentions of MTEM in WallStreetBets Daily Discussion

MTEM News

Recent insights relating to MTEM

CNBC Recommendations

Recent picks made for MTEM stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MTEM

Corporate Flights

Flights by private jets registered to MTEM